💉

AOD-9604

AOD-9604 is a 16-amino acid fragment of the tail end of human growth hormone, engineered in the early 2000s as an obesity drug. The pitch was elegant: take the part of GH that drives fat burning, leave behind the parts that raise blood sugar and IGF-1, and you get the fat loss of growth hormone without the metabolic baggage. It works that way in obese mice. It mostly didn't work that way in humans.
Most people interested in AOD-9604 today are using it off-label for fat loss, often stacked with peptides like
💉
CJC-1295
+
💉
Ipamorelin
or alongside a GLP-1 like
💉
Semaglutide
. The honest framing is that this is a peptide whose reputation is built on animal data, a single modest-effect Phase 2a trial, and a strong community anecdote, not on robust human clinical evidence. The Phase 2b trial that was meant to be the registration study didn't beat placebo, development was terminated in 2007, and the molecule has since pivoted to being studied for joint cartilage instead. It's worth understanding that picture before deciding whether it's worth the injections.

Deep-dive

AOD-9604 is the C-terminal fragment of human growth hormone, residues 177-191, with an additional tyrosine added to the N-terminus to stabilise the molecule. The full GH molecule has multiple functional domains, the receptor-binding domain in the middle drives the IGF-1 axis and growth effects, and the C-terminal tail appears to drive lipolysis through a separate pathway that doesn't require GH receptor binding. The original Monash University work in obese mice showed AOD-9604 reproduced GH's effect on body weight, fat oxidation, and lipolysis without binding the GH receptor and without inducing the hyperglycaemia or insulin resistance that intact GH causes. This was the foundational mechanistic claim and the reason the molecule was pursued as a drug.
Mechanism in plain terms. The peptide appears to act on adipocytes directly, upregulating beta-3 adrenergic receptor expression and increasing hormone-sensitive lipase activity. In practical terms, this means it nudges fat cells toward breaking down stored triglycerides and increases fat oxidation. Critically, it does not stimulate IGF-1, does not bind the GH receptor, and does not change insulin sensitivity or glucose tolerance, which is the entire reason it exists as a separate molecule rather than just using GH or
💉
Tesamorelin
. This is the cleanest distinguishing feature of AOD-9604 versus the GHRH/GHRP peptides.
The Phase 2a trial. In a 12-week trial of 300 obese adults testing oral doses of 0, 1, 5, 10, 20, and 30 mg daily, the 1 mg group lost 2.6 kg versus 0.8 kg on placebo. That's a 1.8 kg drug-placebo difference over 12 weeks, statistically significant but clinically modest. Curiously, higher doses produced less weight loss, an inverted-U dose response that the trial sponsors interpreted as receptor saturation and which made 1 mg the lead dose for the next phase. Cholesterol and triglycerides also improved modestly.
The Phase 2b trial that ended development. Metabolic Pharmaceuticals then ran a 24-week Phase 2b trial in 536 obese adults at lower doses, the OPTIONS study, intended to be the pivotal efficacy study for registration. The primary weight-loss endpoint at 12 weeks was not met, and the company terminated development of AOD-9604 as an obesity drug in 2007. This is the data point that tells you the most about whether to expect meaningful fat loss from this compound. A pooled meta-analysis of the human trial program (around 900 participants total across six randomised placebo-controlled trials) found no statistically significant difference in fat mass or body weight versus placebo overall. The peptide was very well tolerated, the trial sponsors emphasised this heavily, but tolerability isn't efficacy.
Why the trials probably failed. A few candidate explanations. Oral bioavailability of a 16-amino acid peptide is inherently poor, gut peptidases will cleave most of it before absorption, and the Phase 2 trials used oral capsules. The genetically obese rodent strains where AOD-9604 worked (Zucker rats, ob/ob mice) are leptin-system models that respond differently to lipolytic interventions than diet-induced human obesity. And the modest 1 mg signal in Phase 2a may have been a statistical artefact that didn't survive a larger, longer trial. The community workaround is to use subcutaneous injection rather than oral dosing, which bypasses the gut bioavailability problem but has never been tested at scale in a controlled trial for weight loss in humans.
Safety, the one strong finding. This is the most replicated and defensible thing about AOD-9604 in humans. A pooled safety review across six placebo-controlled trials found the side effect profile was indistinguishable from placebo. No changes in fasting glucose, fasting insulin, oral glucose tolerance, or serum IGF-1. No edema, no carpal tunnel symptoms, no joint aches. No cardiovascular signals. This is the inverse of what you see with
💉
Tesamorelin
or exogenous GH, where the glucose impact is the main reason to monitor. The trade-off is that the things AOD-9604 doesn't do safety-wise are also things it doesn't seem to do efficacy-wise. The molecule is largely metabolically silent.
Cartilage and osteoarthritis. After the obesity programme was shelved, AOD-9604 was licensed for development as an intra-articular treatment for knee osteoarthritis. A rabbit model of collagenase-induced knee OA showed intra-articular AOD-9604 reduced cartilage degeneration scores and improved lameness, and the combination of AOD-9604 plus hyaluronic acid outperformed either alone. Human trials in osteoarthritis are limited and have not produced approval anywhere. This is currently the most active area of pharmaceutical development for the molecule, though it's a different use case and a different route of administration than what off-label users are pursuing.
Anecdotal pattern in off-label use. Across the off-label community, the reported pattern with subcutaneous AOD-9604 at 250-500 mcg daily is something like: modest reduction in subjective abdominal fat over 2-3 months, no change in appetite (this is consistent with mechanism, AOD-9604 isn't a GLP-1 and doesn't suppress hunger), and a clean side effect profile that matches the trial data. Reports are split, a substantial subset of users say they noticed nothing. The most consistent positive reports come from people stacking it with
💉
CJC-1295
+
💉
Ipamorelin
, where the GH pulse plus AOD's direct adipocyte effect are claimed to be additive, though there's no controlled human evidence for this combination. The compound is also popular as a "fat partitioning" agent alongside
💉
Semaglutide
or
💉
Tirzepatide
, on the theory that GLP-1s reduce total body weight including muscle while AOD nudges body composition toward more fat-specific loss. Again, this is anecdote-driven, not trial-supported.
Women. The Phase 2 trials enrolled both sexes and didn't find sex-specific responses, though the trials weren't powered to detect them. There's no female-specific dosing literature for AOD-9604. Mechanistically, beta-3 adrenergic receptor density in adipose tissue is influenced by oestrogen, and women in lower-oestrogen states (postmenopause, late luteal) may theoretically have different receptor environments, but this is speculation. Visceral fat accumulation accelerates around the menopausal transition as endogenous GH output drops, and the same period is when women often look at peptides for body composition. The honest answer is that AOD-9604 hasn't shown convincing fat loss in either sex in controlled trials, so any female-specific framing inherits the same weak evidence base. Skip in pregnancy and breastfeeding, no safety data.
Older adults. No specific trial data in older adults. GH output drops with age and lipolytic responsiveness declines, which is part of why
💉
Tesamorelin
shows clear effects in middle-aged adults with visceral fat accumulation. AOD-9604 doesn't have the same mechanism and doesn't have the equivalent evidence base in this population.
How AOD-9604 compares to the alternatives. For fat loss specifically: GLP-1 agonists (
💉
Semaglutide
,
💉
Tirzepatide
,
Retatrutide
Retatrutide
) produce 15-25% body weight loss in placebo-controlled trials and are the actual standard of care now.
💉
Tesamorelin
produces 15-20% visceral fat reduction over 6 months in trial data but raises insulin resistance.
💉
CJC-1295
+
💉
Ipamorelin
raises GH pulses and produces modest body composition changes over months. AOD-9604 sits below all of these on evidence strength for fat loss in humans. Its main remaining argument is the clean side-effect profile and the absence of any IGF-1 or glucose impact, which is genuinely unique in this category.
Limitations of the evidence. No successful Phase 3 trial, ever. The pivotal Phase 2b trial failed its primary endpoint. The favourable trial reports in the popular literature mostly cite the 1 mg arm of the smaller Phase 2a trial in isolation. The mechanism work is largely from one research group in the early 2000s and has not been replicated by independent labs at the same depth. The osteoarthritis indication is in early-stage development with limited human data. There are no head-to-head trials against any other fat-loss peptide or pharmaceutical. The subcutaneous route used by the off-label community has never been tested in a controlled human weight-loss trial.

Dosage:

  • Standard off-label subcutaneous dose: 250-500 mcg once daily, injected subcutaneously into the abdomen. The community-typical dose is 300 mcg. Note that this is empirical, not trial-validated, the human trials used oral dosing at 1-30 mg
  • Timing: Most users inject in the morning on an empty stomach. Some inject pre-cardio on the theory that the lipolysis signal pairs with the fat oxidation of fasted cardio. There is no trial evidence supporting either timing pattern over the other
  • Reconstitution: Supplied as lyophilised powder, typically in 2 mg or 5 mg vials. Reconstitute with bacteriostatic water, store refrigerated, use within roughly 30 days. Subcutaneous injection with an insulin syringe, rotate sites
  • Cycling: Off-label protocols commonly run 8-12 weeks on, 4 weeks off, though there's no biological reason this schedule is required and no comparative data on continuous versus cycled dosing. The Phase 2 trials ran continuous daily dosing for 12-24 weeks without tolerance issues or safety signals
  • Stacking: Most commonly stacked with
    💉
    CJC-1295
    +
    💉
    Ipamorelin
    on the theory that the GH pulse and direct adipocyte effect are additive. Also commonly stacked alongside
    💉
    Semaglutide
    or
    💉
    Tirzepatide
    for fat-specific loss during caloric deficit. Neither combination has controlled human trial support
  • Women: No specific dose adjustment. The trials enrolled both sexes at the same doses. Skip in pregnancy and breastfeeding
  • Sourcing: AOD-9604 was placed on the FDA's 503A Category 2 list in September 2023, which restricted legitimate US compounding pharmacy access. The nomination was subsequently withdrawn and the regulatory situation is in flux as of 2026, with the Pharmacy Compounding Advisory Committee scheduled to re-review several peptides. In practice this means most US sourcing currently goes through grey-market "research use only" channels where identity and dose accuracy are unreliable. Outside the US, availability varies by jurisdiction

Here's what you can expect:

In the wrong context (already lean, modest dose, short duration, oral route), realistically very little. The most consistent finding in the trial program was that AOD-9604 was indistinguishable from placebo on most subjective and metabolic measures.
In the typical off-label context (subcutaneous, 250-500 mcg daily, 8-12 weeks, alongside training and diet), the reported pattern is a slow shift in body composition over months rather than a noticeable change in weight on the scale. No appetite change, no GH-related side effects like joint aches or water retention, no flushing. The honest expectation should be: if you notice anything at all, it'll be subtle and slow, and it's hard to separate from the diet and training effort you're already putting in.
With no calorie deficit and no training, expect nothing meaningful. AOD-9604 is not a weight-loss drug in the GLP-1 sense, it doesn't reduce intake, doesn't suppress hunger, doesn't change satiety signalling. It's a peripheral lipolytic signal, and lipolysis without a calorie deficit just means free fatty acids cycle back into storage.

Side effects & risks:

  • Injection site reactions are the most common issue, mild redness or itching. Rotate sites
  • The clean profile is the headline. Across roughly 900 trial participants, AOD-9604 produced no detectable changes in fasting glucose, fasting insulin, oral glucose tolerance, IGF-1, or thyroid function, and side effects were indistinguishable from placebo. This is the cleanest safety profile of any peptide in the GH-adjacent category
  • Headache and fatigue were reported at low rates in the trials but not at higher rates than placebo
  • No IGF-1 elevation, which means no carpal tunnel symptoms, no edema, no joint aches, no theoretical cancer-promotion concern from elevated IGF-1. This is the practical safety advantage versus
    💉
    Tesamorelin
    or exogenous GH
  • No glucose or insulin impact in the trial data. This is the practical advantage versus
    💉
    Tesamorelin
    , which can move fasting glucose into prediabetic range
  • Pregnancy and breastfeeding: avoid, no safety data
  • Active cancer: while AOD-9604 doesn't elevate IGF-1 and the mechanistic concern is lower than with GH or tesamorelin, there's no human cancer-population data, and the conservative default is to avoid
  • Long-term safety beyond 6 months in humans is essentially unknown. The longest controlled human trial ran 24 weeks. The mechanism (direct adipocyte action without systemic GH effects) doesn't suggest obvious long-term concerns, but the data simply doesn't exist
  • Product quality is the real risk. Because AOD-9604 sits in the grey-market peptide space in most jurisdictions, the actual content of the vial varies. This is the practical risk that most users underweight, you can do everything right and still be injecting something that isn't AOD-9604, or isn't at the labelled concentration. Third-party testing of the source is the only meaningful mitigation
  • WADA prohibits it as a peptide hormone analogue, even though IGF-1 doesn't rise. Don't use it if you compete in tested sport

🩸

Blood markers

Fasting glucose, fasting insulin, HbA1c, baseline. AOD-9604 doesn't appear to shift these in trial data, but if you're stacking it with
💉
CJC-1295
+
💉
Ipamorelin
, the stack will, and you want a baseline before starting.
IGF-1, baseline if you're stacking with any GHRH or GHRP peptide. AOD-9604 alone won't move IGF-1, but the stack will, and IGF-1 is the practical marker of GH-axis intensity.
Full lipid panel, baseline and at 3 months. The Phase 2 data showed modest improvements in triglycerides and total cholesterol on AOD-9604, worth tracking if this is part of your reason for using it.
Waist circumference and ideally a DEXA body composition scan, baseline and at 3 months. The relevant outcome is fat distribution, not total weight, and the scale alone is a poor proxy. If you're paying for this peptide and the injections, measure whether anything is actually changing.
For AOD-9604 used alone, the practical minimum is fasting glucose + lipid panel + waist circumference at baseline and 3 months. The clean metabolic profile means heavy bloodwork isn't required for safety, the case for tracking is to know whether the compound is doing anything at all for you.
Not approved for human use in any jurisdiction. Was placed on FDA 503A Category 2 list in 2023, regulatory status under review as of 2026.